The delphi method of decision making was used to address an unusual clinical case in which various aspects of the case required opposing management strategies.
T
he delphi approach to decision making "may be characterized as a method for structuring a group communication process so that the process is effective in allowing a group of individuals as a whole to deal with a complex problem."l This consensus method requires the selection of a panel of experts and repeated surveying of these experts, presumably until a convergence of opinion has been reached.
The d e l~h i method has been used to address issues in a wide variety of subject areas,I including the health field.2-13 Faced with an "insoluble" treatment problem, we used a delphi analysis of experts. The value of a treatment delphi is that a knowledgeable group of busy clinicians located in various parts of the country can provide recommendations for the treatment of a difficult clinical case. The purpose of this article is to explore the feasibility of such an approach and to suggest modifications for future treatment delphi surveys.
identified. Review of the literature revealed no guidelines regarding management. Various aspects of the case were cwnsidered to require opposite strategies of management.
A panel of 30 pulmonary specialists was chosen for this survey; all are members of the American Thoracic Society (ATS) and were c~)nsidered experts in the area of tuberculosis. Round 1 of the survey of experts was mnducted during September 1989. The following clinical case description was sent to each panelist: A 43-year-old black woman presented to the medical service of a ~lniversity hospital with hepatic cwma. She was well until approxim;rtely two months prior when she discovered that both women with whom she was sharing living space for two years had active pulmonary tuberculosis. In one case the disease was fatal. The patient's last rec~)llection of a purified protein derivative (PPD) test was many years prior and was "negative." During cwntact follow-up, a 5 TU PPD was placed that was "positive." The patient was placed on a regimen of isoniazid (INH), 300 mg, which she tcwk daily for approximately four weeks when she developed jaundice followed by fulminant hepatic failure. At an area hospital, her liver profile revealed a bilirubin level of 17, SGOT of 8,444, and alkaline phosphatase of 681. A liver biopsy specimen was "n)nsistent with drug-induced liver disease." She was then transferred to the Sammy Davis, Jr Liver Institute for management of her liver disease. On transfer, the liver profile revealed a bilirubin level of 22, SCOT of 107. SGPT of 535, alkaline phosphatase of 338, and prothrom1)in time of 51.7 s. At this time, the patient was in hepatic emma. The day following transfer, she received a liver transplant. On pathologic examination, her liver revealed fi~lminant hepatic necrosis. After transplantation, her encephalopathy rapidly resolved. At the time of hospital discharge, the liver profile revealed a bilirubin level of 1.7, SCOT of 23, SGPT of 37, and alkaline phosphatase of 203. The patient is currently k i n g treated with prednisone, 20 mg daily, cyclosporine, 400 mg twice daily, and mthioprine, 50 mg daily, and will continue to receive this regimen indefinitely At this point, the immunosuppressed household amtact of two active cases of tubercr~losis has presumably not received adequate preventive therapy For her tuberc~~losis infection. Which of the Approximately two months later, n)nnd 2 of the delphi survey was mailed to all of the experts and included a description of the clinical case along with the treatments identified as clinically useful by the panelists during round 1. Experts were then asked to rank the appropriateness of the proposed treatments on a scale from 1 to 9, with 1 being extremely inappropriate, 5 being equivocal, and 9 being extremely app~)priate.'.~ An "appropriate" treatment is defined as one where the expected health benefits exceed the expected negative mnsequences by a sufficiently wide margin so that the treatment is worth carrying out. An "inappropriate" treatment is defined as one where the negative cwnsequences outweigh the expected benefits by a sufficiently wide margin so that the treatment is not worth doing. During round 2 of the survey, experts were also asked to propose any additional treatment approaches not already included in the delphi. Ninety percent (ie, 27) of the experts returned the round 2 delphi survey Round 3 of the delphi was distributed in February 1990, and included the graphic presentation of the responses from round 2 along with a reminder of one's own previous responses and a restatement of the case. Each expert was then asked to consider hisher opinions in the cuntext of the gnmp's judgment and to remnsider hisher individual resoonses.
However, during the time period between rounds 2 and 3, a journal article and an editorial directly related to tuberculosis preventive therapy appeared in the American Review of Respiratory Disecrse~.~~ TO ensure that all delphi participants were basing their round 3 responses on the same information, copies of the article and editorial were included with the nmnd 3 survey In addition, two questions were asked: "Have the enclosed articles influenced has been reached. your choice?" and "Have the opinions of the other participants influenced your choice?" Finally, the participants were once again given the opportunity to propose additional treatment approaches. Twenty-three of the round 2 participants (ie, 85 percent response rate) returned the round 3 survey.
Although in each mund respondents were appraised of their mlleagues' opinions as a group, to reduce the possibility of communication other than through the delphi procedures, no individuals were identified according to their responses and a list of the delphi panelists was not distributed.
The delphi survey data were analyzed using the SAS statistical computer package.lB The distribution of responses is described using measures of central tendency (ie, the mean or the median) and measures of variability (ie, the standard deviation or interquartile range-the difference between the 25 percent and the 75 percent values). In addition, visual examination of round 2 and 3 responses provides additional information needed to interpret the results of the delphi survey. For this analysis, consensus is assumed to have been reached if the measure of variability is small (ie, if the interquartile range of any round is 2 or less in the nine point appropriateness scale). In addition, median values are used to identlfy the level of appropriateness for a given treatment.
RESULTS
For the specific patient who was considered to have both a universal indication for and a universal contraindication against preventive therapy, a total of nine treatments were considered by the expert panelists during the three-round delphi survey; eight treatments were evaluated during round 2 and one additional treatment was added by a round 2 participant. The results of round 2 (Table 1) suggest that these experts would opt for either treatment with rifampin, 600 mg for 4 or 12 months, or "no treatment with close observation," since the median values for these three distributions were 5 or greater. Although the median value for "no treatment with close observation" was much higher on the appropriateness scale than the rifampin treatments, the diversity of opinion on the appropriateness of this treatment is obvious when one considers the size of the interquartile range (ie, 8 vs 4 for the rifampin treatments). After round 3 of the delphi (Table 2) , consensus was reached on seven of the nine proposed treatments. Among these seven were the following: INH, 300 mg daily for 12 months; ethambutol, 25 mgkg daily for 12 months; ethambutol, 25 mgkg daily and pyrazinamide, 1.5 g daily for 6 months; and ciprofloxacin, 500 mg twice daily for 6 months; all had median scale values that suggest that the panelists believed these treatments to be clinically inappropriate. An examination of the round 2 and 3 responses in Figure 1 presents a visual confirmation of the picture suggested by the summary statistics for each distribution.
The administration of rifampin, 600 mg daily for 4 months, rifampin, 600 mg daily for 12 months, and rifampin, 600 mg daily and pyrazinamide, 1.5 g daily for 2 months was considered to be of equivocal value to the proposed case. However, by round 3, rifampin, 600 mg for 4 months, was clearly the most preferred of the treatments considered to be of equivocal value (median value = 5). Visual inspection of the round 2 and 3 distributions for this treatment option suggests that almost equal numbers of experts believed this treatment to be either appropriate or inappropriate (Fig 2) .
Finally, there were two treatments for which a consensus was not reached (rifampin, 600 mg daily with ethambutol, 25 mgkg daily for 12 months and "no treatment with close observation"). Despite this lack of consensus, the magnitude of the median values for these possible treatments and the direction of change in these values suggest that these experts believe the rifampin and ethambutol combination treatment to be inappropriate and that "no treatment Rifampin 600 mg daily and Pyrazinamide 1.5 gm daily for 2 months with close observation" is possibly an appropriate treatment (Fig 3) .
Thus, after considering the results of the threeround delphi, a split appeared regarding the most reasonable treatment protocol: rifampin, 600 mg daily for four months or no treatment with close observation.
In an attempt to see if any difference in treatment choice might be attributed to some characteristic of the delphi experts, the panelists were identified by delphi experts; the median "influence" value for the articles was 3.5 (mean=4.2, SD=2.2) while the median "influence" value for the opinions of the other participants was only 2.9 (mean = 2.9, SD = 2.1). Statistical analysis of the distributions of responses using a Wilcoxon sign rank test17 (ie, the nonparametric analogue to a paired t test) confirms that there was a significant difference in "influence" level at the 0.05 significance level, with a p value of 0.0153. Interestingly, even though the panelists believed that the journal article influenced their decision to a greater extent than did the opinion of the other panelists, the perceived influence of both of these factors was quite small (ie, on the low end of the influence scale), despite the obvious shift in responses that has been illustrated in Figures 1 through 5 .
Preventive therapy (chemoprophylaxis) is given because of the realization that tuberculous infection, which always precedes active disease, occurs with few organisms that can be reduced or eliminated using one inexpensive drug-INH given for 6 to 12 months.'" Isoniazid is the only drug proved effective for this indication. researcher^.^-^^^^^ The methods used to conduct these surveys have varied from repeated surveying of experts, as in our study, to "modified" delphi surveys involving a two-step process: an initial round and then a conference where all participants meet to discuss their response^.^-^ They have also involved panels as small as 9 and as large as 400 expert^.^," Unfortunately, few authors report the time interval between rounds.
This time interval may be less important for policy surveys, but it could be an issue for delphi surveys relating to the treatment of a particular patient. These methodologic differences must be considered when comparing the responses rates of these studies. Our three-round survey response rate was 23/30 or 77 percent. This response rate is a little better than the 75 percent response rate found in a previous tworound delphi survey performed by C D C in 1981." The C D C delphi looked at preventive therapy for organisms resistant to INH and consensus was reached on treatment with rifampin. While several of the panelists were the same as in the current delphi, some of the survey methods differed.
Our survey results were very surprising in the dearth of opinion regarding a secondary drug for preventive therapy. However, we did find some difference in treatment preferences for those who worked in a university setting vs those in a non-university setting; those in a nonuniversity setting favored treatment with rifampin, 600 mg daily for 4 months, over no treatment with close observation. Since we did not collect demographic information on the respondents, we were unable to see if anv of these factors were related to their responses. However, in general, the 9 non-university respondents were a little more likely than the 13 university-affiliated respondents to have been influenced by the opinions of others (median score on a scale from 1 to 9 was 3 compared with 2 for university-affiliated experts) and by the articles provided during the survey (median of 4 compared with 3 for the university-affiliated experts).
Our study revealed several unacceptable interventions but only two possibly acceptable interventions on how to handle a-patient at extremely high risk of tuberculosis activation. One possible reason for our inability to reach a strong consensus on a treatment may stem from the static nature of the conventional paper-and-pencil delphi survey. A more fruilful approach to the treatment delphi may b e to use a "delphi conference" technique where all responses are entered into a computer conferencing system.22 The -.
computer could be programmed to synthesize the group responses, provide additional information when required, and provide quick feedback to all delphi panelists, thereby increasing the clinical value of such an approach.
